COMMUNIQUÉS West-GlobeNewswire

Alamar Biosciences Launches NULISAseq™ Immune 340 Panel for Comprehensive Profiling of the Immune Proteome
28/07/2026
Expanded panel advances the understanding of immune system across translational and clinical research in cancer, cardiovascular and metabolic diseases, autoimmune diseases and aging | Highly sensitive multiplex [...]
Solésence To Report Second Quarter 2026 Financial Results and Host a Conference Call on August 11
28/07/2026
ROMEOVILLE, Ill., July 28, 2026 (GLOBE NEWSWIRE) -- Solésence, Inc. (Nasdaq: SLSN), a leader in scientifically-driven health care solutions across beauty and life science categories, today announced that the Company [...]
vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
28/07/2026
HIGH POINT, N.C., July 28, 2026 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin , a novel, potential first-in-class oral [...]
Scientists Turn COVID-19 Immune Memory into a Powerful New Ally Against Cancer
28/07/2026
Nature Communications Publishes Breakthrough Study Showing How COVID-Era Immune Memory Can Be Redirected to Fight Cancer Celloram, Inc., University Hospitals, and Case Western Reserve University unveil PROTEXI, a novel [...]
PETVIVO HOLDINGS ANNOUNCES TERMINATION AND SETTLEMENT AGREEMENT WITH VETSTEM
28/07/2026
Agreement Resolves All Outstanding Matters and Completes Transition of PrecisePRP ® Product Line MINNEAPOLIS, July 28, 2026 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQX: PETV; OTCID: PETVW) working in cooperation [...]
Seer Stockholders Vote to Re-Elect All Seven of Seer’s Director Nominees at 2026 Annual Meeting
28/07/2026
REDWOOD CITY, Calif., July 28, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER) (“Seer”) today announced that, based on the preliminary voting results from Seer’s 2026 Annual Meeting of Stockholders (the “Annual [...]
EssilorLuxottica: Q2/H1 2026 Results - Solid revenue trajectory at +9.7% in H1, with Q2 at +8.7%. Increasing profitability, with Adj. Operating Profit +15%.
28/07/2026
Solid revenue 1 trajectory at +9.7% in H1, with Q2 at +8.7% Increasing profitability, with Adj. Operating Profit 1,2 +15% Group’s revenue grew 9.7% in H1 at constant exchange rates 1 , with Q2 at +8.7% Retail comparable [...]
North Texas Plastic Surgery’s Dr. Sacha Obaid Named to Newsweek’s America’s Best Plastic Surgeons 2025 List
28/07/2026
Recognition spans five procedure categories, including breast augmentation, liposuction, rhinoplasty, eyelid surgery and tummy tuck SOUTHLAKE, Texas, July 28, 2026 (GLOBE NEWSWIRE) -- North Texas Plastic Surgery [...]
SodaSlim Introduces a Gummy Supplement Format as Part of Its Portfolio Expansion
28/07/2026
SodaSlim Gummies expand the company’s product portfolio following a coordinated development cycle covering formulation design, production planning, packaging preparation and quality review. New York City, July 28, 2026 [...]
AscellaHealth Appoints Industry Veteran Johanna van Nijkerk as Vice President of Business Development to Advance National Accounts and Drive Growth of AscellaOne
28/07/2026
BERWYN, Pa., July 28, 2026 (GLOBE NEWSWIRE) -- AscellaHealth , a full-spectrum pharmacy solutions provider rooted in specialty pharmacy expertise, today announces the appointment of Johanna van Nijkerk as vice president [...]
Colorectal Cancer Doesn’t Care How Young You Are
28/07/2026
Alliance’s Never Too Young Taskforce Tackles Growing Crisis as Cases of the Deadliest Cancer Continue to Rise in People Under 50 Key Takeaways: This August, World Cancer Support Month, the Colorectal Cancer Alliance ( [...]
Pennant Announces Second Quarter 2026 Earnings Release and Call
28/07/2026
EAGLE, Idaho, July 28, 2026 (GLOBE NEWSWIRE) -- The Pennant Group, Inc. (NASDAQ: PNTG), the parent company of operating subsidiaries that provide home health, hospice and senior living services, announced today that it [...]
EssilorLuxottica: Résultats T2/S1 2026 - Trajectoire solide du chiffre d’affaires à +9,7 % au S1, avec un T2 à +8,7 %. Rentabilité en hausse, avec un résultat opérationnel ajusté progressant de +15 %.
28/07/2026
Trajectoire solide du chiffre d’affaires 1 à +9,7 % au S1, avec un T2 à +8,7 % Rentabilité en hausse, avec un résultat opérationnel ajusté 1,2 progressant de +15 % Chiffre d’affaires du Groupe en hausse de +9,7 % au S1 [...]
Eurobio Scientific: Premier semestre 2026, Continuation de la transformation stratégique
28/07/2026
PREMIER SEMESTRE 2026, CONTINUATION DE LA TRANSFORMATION STRATEGIQUE Progression du chiffre d’affaires semestriel de 5% à 84,5 M€ Continuation de la stratégie du Groupe : Produits propriétaires : 37% du Chiffre d’ [...]
Eurobio Scientific: First half of 2026, Continuation of the strategic transformation
28/07/2026
FIRST HALF OF 2026, CONTINUATION OF THE STRATEGIC TRANSFORMATION First-half revenue up 5% to €84.5 million Continuation of the Group’s strategy: Proprietary products: 37% of revenue International expansion: 47% of [...]
RECORDATI: SOLID MOMENTUM OF THE GROUP CONTINUES FIRST HALF 2026. NET REVENUE +6.6%, EBITDA +8.8%, ADJUSTED NET INCOME +6.7%
28/07/2026
Consolidated net revenue of € 1,410.8 million in the first half of 2026, +6.6% or +9.1% on a like-for-like basis ( 3) at constant exchange rates (CER); adverse FX impact of € 34.5 million (-2.6%) EBITDA ( 1) of € 540.2 [...]
Grief goes global on screen as first-of-its-kind festival receives over 500 films from six continents
28/07/2026
Filmmakers across more than 50 countries submitted work on loss and healing, signaling cinema's growing power as a shared language for grief. New York, NY, July 28, 2026 (GLOBE NEWSWIRE) -- Grief Fest™ , the first [...]
Standard BioTools Announces Sale of Mass Cytometry Business and Illumina’s Buyout of Contingent Payments to Advance Merger with Treeline Biosciences
28/07/2026
Sale of Mass Cytometry Business to Multiplex Bio Ensures Full Continuity of CyTOF and Hyperion Product Lines, Customer Relationships, Dedicated Team and Continued Investment in Next Generation Multiplex Platforms [...]
Pluri Advances Commercial Expansion Through Its Subsidiary Cellav, Completing Regulatory Registration in the UK
28/07/2026
UK regulatory registration supports commercial launch of regenerative aesthetics portfolio in a marke t with an estimated size of ~$900 million annual ly , an d strengthens the foundation for broader international [...]

Pages